SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2011
Aegerion Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
101 Main Street, Suite 1850
Cambridge, Massachusetts 02142
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
(b) Resignation of a Principal Officer
On June 8, 2011, William Lewis resigned as President of Aegerion Pharmaceuticals, Inc. (the Company). Mr. Lewis has left the Company to pursue other interests. Mr. Lewiss responsibilities at the Company will be assumed by Marc Beer, Chief Executive Officer.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.